High adherence to the Mediterranean diet is associated with a reduced risk for SLE, with the relationship partially mediated by certain liver and kidney function biomarkers.

RemeGen announced that it plans to submit a Biologics License Application (BLA) to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for primary ...

Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected ...

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...

Zenas BioPharma, Inc. ( ($ZBIO) ) has released its Q2 earnings. Here is a breakdown of the information Zenas BioPharma, Inc. presented to its ...

Autolus Therapeutics ( ($AUTL) ) has released its Q2 earnings. Here is a breakdown of the information Autolus Therapeutics presented to its ...

Net loss was $23.0 million, or $0.31 per basic and diluted share, for the second quarter of 2025. This net loss includes non-cash charges of $3.4 million that consisted primarily of share-based ...

Using data from over 1.5 million patients from 47 studies, the researchers analysed the association between four autoimmune ...

Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of Budoprutug in Primary Membranous Nephropathy (pMN) Expected to Initiate in the ...

Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - ...

Company reports Q2 2025 AUCATZYL® net product revenue of $20.9 million and $29.9 for the first six months of 2025Company recently received conditional marketing authorization from U.K. Medicines and H ...

Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of ...